Intrinsic value of Myomo - MYO

Previous Close

$1.99

  Intrinsic Value

$0.25

stock screener

  Rating & Target

str. sell

-87%

Previous close

$1.99

 
Intrinsic value

$0.25

 
Up/down potential

-87%

 
Rating

str. sell

We calculate the intrinsic value of MYO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  2
  4
  6
  8
  12
  16
  22
  29
  37
  46
  58
  71
  85
  101
  119
  138
  159
  182
  206
  232
  259
  287
  317
  349
  381
  415
  451
  488
  526
  566
Variable operating expenses, $m
  10
  15
  23
  33
  47
  65
  87
  114
  147
  186
  231
  282
  340
  405
  476
  553
  637
  728
  824
  927
  1,035
  1,149
  1,269
  1,394
  1,525
  1,661
  1,804
  1,951
  2,105
  2,265
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  10
  15
  23
  33
  47
  65
  87
  114
  147
  186
  231
  282
  340
  405
  476
  553
  637
  728
  824
  927
  1,035
  1,149
  1,269
  1,394
  1,525
  1,661
  1,804
  1,951
  2,105
  2,265
Operating income, $m
  -7
  -12
  -17
  -25
  -35
  -49
  -65
  -86
  -110
  -139
  -173
  -212
  -255
  -303
  -357
  -415
  -478
  -546
  -618
  -695
  -776
  -862
  -952
  -1,046
  -1,144
  -1,246
  -1,353
  -1,464
  -1,579
  -1,699
EBITDA, $m
  -7
  -12
  -17
  -25
  -35
  -49
  -65
  -86
  -110
  -139
  -173
  -211
  -255
  -303
  -356
  -414
  -477
  -545
  -617
  -694
  -775
  -860
  -950
  -1,044
  -1,142
  -1,244
  -1,350
  -1,461
  -1,576
  -1,696
Interest expense (income), $m
  0
  0
  0
  0
  0
  1
  1
  1
  2
  3
  4
  4
  6
  7
  8
  10
  12
  14
  16
  18
  21
  23
  26
  29
  32
  35
  38
  42
  45
  49
  53
Earnings before tax, $m
  -7
  -12
  -17
  -25
  -36
  -50
  -67
  -88
  -113
  -143
  -178
  -217
  -262
  -312
  -367
  -427
  -492
  -562
  -636
  -716
  -799
  -888
  -980
  -1,077
  -1,179
  -1,284
  -1,394
  -1,509
  -1,628
  -1,752
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -7
  -12
  -17
  -25
  -36
  -50
  -67
  -88
  -113
  -143
  -178
  -217
  -262
  -312
  -367
  -427
  -492
  -562
  -636
  -716
  -799
  -888
  -980
  -1,077
  -1,179
  -1,284
  -1,394
  -1,509
  -1,628
  -1,752

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  3
  5
  7
  10
  14
  20
  27
  35
  45
  57
  71
  86
  104
  124
  146
  169
  195
  223
  252
  284
  317
  352
  388
  427
  467
  508
  552
  597
  644
  693
Adjusted assets (=assets-cash), $m
  3
  5
  7
  10
  14
  20
  27
  35
  45
  57
  71
  86
  104
  124
  146
  169
  195
  223
  252
  284
  317
  352
  388
  427
  467
  508
  552
  597
  644
  693
Revenue / Adjusted assets
  0.667
  0.800
  0.857
  0.800
  0.857
  0.800
  0.815
  0.829
  0.822
  0.807
  0.817
  0.826
  0.817
  0.815
  0.815
  0.817
  0.815
  0.816
  0.817
  0.817
  0.817
  0.815
  0.817
  0.817
  0.816
  0.817
  0.817
  0.817
  0.817
  0.817
Average production assets, $m
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  2
  2
  3
  3
  3
  4
  5
  5
  6
  6
  7
  8
  9
  10
  10
  11
  12
  13
  14
Working capital, $m
  -1
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -12
  -15
  -19
  -23
  -28
  -33
  -39
  -45
  -52
  -59
  -67
  -75
  -84
  -93
  -103
  -113
  -124
  -135
  -147
  -159
  -171
  -184
Total debt, $m
  0
  1
  3
  5
  7
  11
  15
  20
  27
  34
  43
  52
  63
  76
  89
  104
  120
  137
  156
  175
  196
  218
  241
  265
  290
  316
  343
  371
  400
  431
Total liabilities, $m
  2
  3
  4
  6
  9
  12
  17
  22
  28
  35
  44
  54
  65
  77
  91
  106
  122
  139
  157
  177
  198
  219
  242
  266
  291
  317
  344
  373
  402
  432
Total equity, $m
  1
  2
  3
  4
  5
  7
  10
  13
  17
  21
  27
  32
  39
  47
  55
  64
  73
  84
  95
  107
  119
  132
  146
  160
  175
  191
  208
  225
  242
  261
Total liabilities and equity, $m
  3
  5
  7
  10
  14
  19
  27
  35
  45
  56
  71
  86
  104
  124
  146
  170
  195
  223
  252
  284
  317
  351
  388
  426
  466
  508
  552
  598
  644
  693
Debt-to-equity ratio
  0.330
  0.800
  1.080
  1.260
  1.380
  1.450
  1.510
  1.540
  1.570
  1.590
  1.600
  1.610
  1.620
  1.630
  1.630
  1.640
  1.640
  1.640
  1.640
  1.650
  1.650
  1.650
  1.650
  1.650
  1.650
  1.650
  1.650
  1.650
  1.650
  1.650
Adjusted equity ratio
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376
  0.376

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -7
  -12
  -17
  -25
  -36
  -50
  -67
  -88
  -113
  -143
  -178
  -217
  -262
  -312
  -367
  -427
  -492
  -562
  -636
  -716
  -799
  -888
  -980
  -1,077
  -1,179
  -1,284
  -1,394
  -1,509
  -1,628
  -1,752
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  2
  3
  3
Funds from operations, $m
  -7
  -12
  -17
  -25
  -36
  -50
  -67
  -88
  -113
  -143
  -177
  -217
  -262
  -311
  -366
  -426
  -491
  -561
  -635
  -714
  -798
  -886
  -979
  -1,076
  -1,177
  -1,282
  -1,392
  -1,506
  -1,625
  -1,749
Change in working capital, $m
  0
  0
  -1
  -1
  -1
  -1
  -2
  -2
  -3
  -3
  -4
  -4
  -5
  -5
  -6
  -6
  -7
  -7
  -8
  -8
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -12
  -13
Cash from operations, $m
  -7
  -11
  -17
  -25
  -35
  -48
  -65
  -85
  -110
  -140
  -174
  -213
  -257
  -306
  -360
  -420
  -484
  -553
  -628
  -706
  -789
  -877
  -969
  -1,065
  -1,166
  -1,271
  -1,381
  -1,494
  -1,613
  -1,736
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -3
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
Cash from investing activities, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -4
Free cash flow, $m
  -7
  -11
  -17
  -25
  -35
  -48
  -65
  -86
  -111
  -140
  -174
  -213
  -258
  -307
  -361
  -421
  -485
  -555
  -629
  -708
  -791
  -879
  -971
  -1,068
  -1,169
  -1,274
  -1,383
  -1,498
  -1,616
  -1,739
Issuance/(repayment) of debt, $m
  0
  1
  1
  2
  3
  3
  4
  5
  6
  7
  9
  10
  11
  12
  14
  15
  16
  17
  18
  20
  21
  22
  23
  24
  25
  26
  27
  28
  29
  31
Issuance/(repurchase) of shares, $m
  8
  12
  18
  27
  38
  52
  69
  91
  117
  147
  183
  223
  269
  319
  375
  436
  502
  572
  647
  727
  812
  901
  994
  1,092
  1,194
  1,300
  1,411
  1,526
  1,646
  1,770
Cash from financing (excl. dividends), $m  
  8
  13
  19
  29
  41
  55
  73
  96
  123
  154
  192
  233
  280
  331
  389
  451
  518
  589
  665
  747
  833
  923
  1,017
  1,116
  1,219
  1,326
  1,438
  1,554
  1,675
  1,801
Total cash flow (excl. dividends), $m
  0
  2
  3
  4
  5
  7
  8
  10
  13
  15
  17
  20
  22
  25
  27
  30
  32
  35
  37
  39
  41
  44
  46
  48
  50
  52
  54
  57
  59
  61
Retained Cash Flow (-), $m
  -8
  -12
  -18
  -27
  -38
  -52
  -69
  -91
  -117
  -147
  -183
  -223
  -269
  -319
  -375
  -436
  -502
  -572
  -647
  -727
  -812
  -901
  -994
  -1,092
  -1,194
  -1,300
  -1,411
  -1,526
  -1,646
  -1,770
Prev. year cash balance distribution, $m
  12
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  5
  -10
  -15
  -23
  -32
  -45
  -61
  -80
  -104
  -133
  -166
  -203
  -246
  -295
  -348
  -406
  -469
  -538
  -611
  -688
  -771
  -857
  -948
  -1,044
  -1,144
  -1,248
  -1,356
  -1,469
  -1,587
  -1,709
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  5
  -9
  -13
  -19
  -25
  -33
  -41
  -50
  -60
  -69
  -79
  -87
  -94
  -99
  -102
  -103
  -102
  -99
  -94
  -87
  -80
  -71
  -62
  -53
  -44
  -36
  -29
  -23
  -17
  -13
Current shareholders' claim on cash, %
  19.1
  3.0
  0.5
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.

FINANCIAL RATIOS  of  Myomo (MYO)

Valuation Ratios
P/E Ratio -0.6
Price to Sales 2.2
Price to Book -0.4
Price to Tangible Book
Price to Cash Flow -0.7
Price to Free Cash Flow -0.7
Growth Rates
Sales Growth Rate 0%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity -60%
Total Debt to Equity -100%
Interest Coverage 0
Management Effectiveness
Return On Assets -200%
Ret/ On Assets - 3 Yr. Avg. -186.7%
Return On Total Capital -800%
Ret/ On T. Cap. - 3 Yr. Avg. -455.6%
Return On Equity 133.3%
Return On Equity - 3 Yr. Avg. -155.6%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 100%
Gross Margin - 3 Yr. Avg. 66.7%
EBITDA Margin -400%
EBITDA Margin - 3 Yr. Avg. -366.7%
Operating Margin -300%
Oper. Margin - 3 Yr. Avg. -300%
Pre-Tax Margin -400%
Pre-Tax Margin - 3 Yr. Avg. -366.7%
Net Profit Margin -400%
Net Profit Margin - 3 Yr. Avg. -366.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MYO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MYO stock intrinsic value calculation we used $1.558866 million for the last fiscal year's total revenue generated by Myomo. The default revenue input number comes from 0001 income statement of Myomo. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MYO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MYO is calculated based on our internal credit rating of Myomo, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Myomo.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MYO stock the variable cost ratio is equal to 400%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MYO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 13.2% for Myomo.

Corporate tax rate of 27% is the nominal tax rate for Myomo. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MYO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MYO are equal to 2.5%.

Life of production assets of 4.3 years is the average useful life of capital assets used in Myomo operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MYO is equal to -32.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $12.445778 million for Myomo - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 12.414 million for Myomo is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Myomo at the current share price and the inputted number of shares is $0.0 billion.

COMPANY NEWS

▶ Myomo® Receives Medicare Codes   [Nov-06-18 12:54PM  Business Wire]
▶ Are Myomo Incs (NYSEMKT:MYO) Interest Costs Too High?   [Oct-25-18 11:04AM  Simply Wall St.]
▶ Do Institutions Own Shares In Myomo Inc (NYSEMKT:MYO)?   [Sep-28-18 12:39PM  Simply Wall St.]
▶ Myomo to Present at The MicroCap Conference   [Sep-18-18 08:00AM  ACCESSWIRE]
▶ Myomo Announces Continued Momentum Across Europe   [Sep-12-18 08:05AM  Business Wire]
▶ Myomo, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ Myomo Appoints Micah Mitchell as Chief Commercial Officer   [Jul-09-18 08:00AM  Business Wire]
▶ Top High Growth Stocks This Week   [Jun-13-18 12:02PM  Simply Wall St.]
▶ Myomo Brings MyoPro to Adolescent Patients   [Jun-06-18 08:00AM  Business Wire]
▶ Myomo, Inc. Issues May 2018 Shareholder Letter   [May-10-18 08:00AM  Business Wire]
▶ Myomo Reports First Quarter 2018 Results   [May-09-18 04:05PM  Business Wire]
▶ Myomo to Report First Quarter 2018 Results on May 9, 2018   [May-03-18 08:00AM  Business Wire]
▶ SeeThruEquity Issues Update on Myomo, Inc.   [Mar-22-18 09:15AM  ACCESSWIRE]
▶ Myomo Welcomes 13 New Center of Excellence Locations   [Mar-12-18 08:00AM  Business Wire]
▶ Myomo, Inc. Issues March 2018 Shareholder Letter   [Mar-08-18 08:00AM  Business Wire]
▶ Myomo Reports Fourth Quarter and Year End 2017 Results   [Mar-07-18 04:05PM  Business Wire]
▶ Myomo to Present at the 30th Annual ROTH Conference   [Mar-05-18 08:00AM  Business Wire]
▶ Myomo and GRE to Conduct Screening Days in Ohio and Detroit   [Feb-14-18 08:00AM  Business Wire]
▶ 8 Stocks That Are Ready to Change Direction   [Jan-29-18 12:00PM  TheStreet.com]
▶ Myomo, Inc. Announces Pricing of Public Offering   [Nov-30-17 08:31AM  Business Wire]
▶ How Financially Strong Is Myomo Inc (MYO)?   [Nov-29-17 05:37PM  Simply Wall St.]
▶ Myomo, Inc. Issues November 2017 Shareholder Letter   [Nov-07-17 08:00AM  Business Wire]
▶ Myomo, Inc. Reports Third Quarter 2017 Results   [Nov-06-17 04:13PM  Business Wire]
▶ Myomo Enters Canadian Market   [Nov-03-17 08:00AM  Business Wire]
▶ Is Myomo Inc (MYO) Growing Too Fast?   [Oct-05-17 09:36AM  Simply Wall St.]
▶ Myomo, Inc. Reports Second Quarter 2017 Results   [Aug-14-17 04:05PM  Business Wire]
▶ Myomo, Inc. Obtains CE Mark Approval for MyoPro®   [Jul-31-17 08:00AM  Business Wire]
▶ Myomo, Inc. Introduces Center of Excellence Program   [Jul-12-17 08:00AM  Business Wire]
▶ Myomo, Inc. to Ring NYSE MKT Closing Bell Today   [Jun-16-17 08:00AM  Business Wire]
▶ Myomo, Inc. Launches MyoPro® 2   [Jun-13-17 08:10AM  Business Wire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.